|
New Products
|
|
|
No proof of efficacy and poorly documented harms
|
|
|
|
|
|
One possibility for patients with no remaining treatment options
|
|
|
|
|
|
Insufficient evaluation in cephalosporin-resistant infections
|
|
|
|
|
|
|
|
Reviews
|
|
|
Prevent, and treat preferably by the oral route
|
|
|
|
|
|
|
Statins and hypotensive drugs: not for everyone
|
|
|
|
|
|
|